Table 4.

Results of Univariate Logistic Regression Analysis of 1-Year Survival Rate.

Subgroup	No. of Studies	No. of Patients	Beta	SE	P
Region	13	175	0.15	0.34	.167
Age	13	175	0.16	0.29	.076
Male	13	175	0.21	0.29	.048
Milan in (%)	12	165	0.04	0.32	.165
Microvascular invasion (%)	10	122	0.17	0.38	.155
Down staging before LT (%)	6	70	0.51	0.44	.133
mTOR-I (%)	11	152	−0.27	0.22	.377
Time to recurrence (months)	12	165	0.13	0.31	.107
Time to progression (months)	8	112	0.57	0.29	.021
Time of onset of sorafenib after recurrence (months)	9	131	0.26	0.30	.076
Initiated dosage (mg/b.i.d.)	13	175	−0.42	0.32	.892
Median duration of sorafenib (months)	7	85	0.74	0.38	.021
Reduction (%)	10	132	−0.41	0.35	.89
Discontinuation (%)	11	152	−0.32	0.27	.809
Hand–foot skin reaction (%)	13	175	−0.01	0.29	.178
Diarrhea (%)	13	175	0.29	0.28	.027
Nausea and vomiting (%)	13	175	−0.03	0.29	.198
Fatigue (%)	13	175	0.24	0.28	.044
Grade 3-4 adverse effects (%)	13	175	0.13	0.30	.079
Partial response (%)	13	175	0.35	0.28	.026
Stable disease (%)	11	152	0.04	0.35	.239
Progression disease (%)	11	152	−0.17	0.34	.489

LT, liver transplantation; SE, standard error.